Photodynamic Therapy for Pseudophakic Eyes Compared to Eyes With Cataract

Ophthalmic Surg Lasers Imaging Retina. 2016 Dec 1;47(12):1132-1136. doi: 10.3928/23258160-20161130-07.

Abstract

Background and objective: Verteporfin photodynamic therapy (vPDT) plays a role in the treatment of chorioretinal conditions. The purpose of this study was to compare vPDT outcomes between cataractous and pseudophakic eyes.

Patients and methods: In this prospective study of consecutive patients with choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD) treated with vPDT, cataract and pseudophakic eyes were compared for number and timing of vPDT treatments, duration of follow-up, angiographic features, and changes in best-corrected visual acuity (BCVA).

Results: Overall, 103 eyes (n = 95) were included in the final analysis; 44 eyes in the cataract group and 59 eyes in the pseudophakic group. No significant difference in change in BCVA (P = .19) or leakage-free CNV lesions (P = .58) was found between the groups.

Conclusions: In this study of vPDT for nAMD, there was no significant difference between eyes with cataract and pseudophakic eyes. It seems that cataract does not clinically alter the effect of vPDT. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1132-1136.].

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cataract / complications*
  • Cataract / diagnosis
  • Cataract / physiopathology
  • Choroidal Neovascularization / complications
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use*
  • Prospective Studies
  • Pseudophakia / complications*
  • Pseudophakia / diagnosis
  • Pseudophakia / physiopathology
  • Time Factors
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity*
  • Wet Macular Degeneration / complications
  • Wet Macular Degeneration / diagnosis
  • Wet Macular Degeneration / drug therapy*

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin